Table 3.
Distribution of genotypes of the -2518 MCP-1 and the CCR2-V64I polymorphism.
| Patients versus controls | ANCA specificity | Diagnosis | Prognosis | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients | Healthy controls | MPO | PR3 | Negative | GPA | MPA | Severe | Nonsevere | |
| MCP-1 -2518 A/G | |||||||||
| A/A | 54.5% (n = 30) | 50% (n = 86) | 63.2% (n = 12) | 50.0% (n = 17) | 0% (n = 0) | 56.4% (n = 22) | 46.7% (n = 7) | 87.5% (n = 14) | 39.5% (n = 15) |
| A/G | 41.8% (n = 23) | 50% (n = 86) | 36.8% (n = 7) | 47.1% (n = 16) | 0% (n = 0) | 38.5% (n = 15) | 53.3% (n = 8) | 12.5% (n = 2) | 59.3% (n = 21) |
| G/G | 3.6% (n = 2) | 0% (n = 0) | 0% (n = 0) | 2.9% (n = 1) | 100% (n = 1) | 5.1% (n = 2) | 0% (n = 0) | 0% (n = 0) | 5.3% (n = 2) |
|
CCR2
V64I |
|||||||||
| G/G | 84.2% (n = 48) | 86.9% (n = 152) | 80.0% (n = 16) | 88.6% (n = 31) | 100% (n = 1) | 90.2% (n = 37) | 73.3% (n = 11) | 84.2% (n = 16) | 86.5% (n = 32) |
| G/A | 14.0% (n = 8) | 12.0% (n = 21) | 20.0% (n = 4) | 8.5% (n = 3) | 0% (n = 0) | 7.3% (n = 3) | 26.7% (n = 4) | 15.8% (n = 3) | 10.8% (n = 4) |
| A/A | 1.8% (n = 1) | 1.1% (n = 2) | 0% (n = 0) | 2.9% (n = 1) | 0% (n = 0) | 2.4% (n = 1) | 0% (n = 0) | 0% (n = 0) | (2.7% (n = 1) |
MCP-1: monocyte chemoattractant protein-1; CCR2: CC chemokine receptor 2; MPO: myeloperoxidase; PR3: proteinase 3; GPA: granulomatosis polyangitis; MPA: microscopic polyangitis. Patients with severe prognosis had significantly higher frequency of the MCP-1 -2518 A/A genotype than patients with less severe prognosis (p < 0.05).